title: Assessing step-therapy programs:a step in the right direction.
authors.affiliation: Medical and Pharmacy Integration Services, Prime Therapeutics, LLC, Eagan, Minnesota, USA. pGleason@primetherapeutics.com
authors.forename: Patrick P
authors.initials: PP
authors.lastname: Gleason
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000191:economics; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics; D000959:Antihypertensive Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D016568:Drugs, Generic / Q000191:economics* / Q000627:therapeutic use; D004608:Eligibility Determination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics*; D007345:Insurance Claim Review / Q000191:economics* / Q000458:organization & administration; D007356:Insurance, Pharmaceutical Services / Q000191:economics*; D008329:Managed Care Programs / Q000191:economics* / Q000458:organization & administration; D017063:Outcome Assessment, Health Care; D012107:Research Design; D016896:Treatment Outcome; D014481:United States
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D016568:Drugs, Generic